Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 49-56

  Cremers, Eline M P ^a   Westers, Theresia M ^a   Alhan, Canan ^a   Cali, Claudia ^a   Wondergem, Mariëlle J ^a   Poddighe, Pino J ^a   Ossenkoppele, Gert J ^a   Van De Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytopenias; Diagnosis; Flow cytometry; Myelodysplastic syndromes

Indexed keywords

ADULT; AGED; ARTICLE; CELL STRUCTURE; CYTOGENETICS; CYTOPENIA; DIAGNOSTIC PROCEDURE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BONE MARROW EXAMINATION; COMPLICATION; DIFFERENTIAL DIAGNOSIS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKOPENIA; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELL; PHENOTYPE; PRE B LYMPHOCYTE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

BIOLOGICAL MARKER; CD34 ANTIGEN; CD45 ANTIGEN; PTPRC PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, CD45; BIOMARKERS; BONE MARROW EXAMINATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKOPENIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; PHENOTYPE; PRECURSOR CELLS, B-LYMPHOID; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84951753192     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.013     Document Type: Article

References (29)

1. P. Greenberg, C. Cox, M.M. LeBeau, P. Fenaux, P. Morel, G. Sanz, and et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
2. J.M. Bennett, D. Catovsky, M.T. Daniel, G. Fladrin, D.A. Galton, H.R. Gralnick, and et al. Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 1982 189 199
3. J.W. Vardiman, N.L. Harris, and R.D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2002 2292 2302 10.1182/blood-2002-04-1199
4. J.W. Vardiman, J. Thiele, D.A. Arber, R.D. Brunning, M.J. Borowitz, A. Porwit, and et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951 10.1182/blood-2009-03-209262
5. A. Tefferi, and J.W. Vardiman Myelodysplastic syndromes New Engl J Med 361 2009 1872 1885 10.1056/NEJMra0902908
6. T.A. Glauser, E.M. Sagatys, J.C. Williamson, B.S. Burton, C. Berger, P. Merwin, and et al. Current pathology practices in and barriers to MDS diagnosis Leuk Res 37 2013 1656 1661 10.1016/j.leukres.2013.10.007
7. J. Schanz, H. Tüchler, F. Solé, M. Mallo, E. Luño, J. Cervera, and et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge J Clin Oncol Off J Am Soc Clin Oncol 30 2012 820 829 10.1200/JCO.2011.35.6394
8. D. Haase, U. Germing, J. Schanz, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, and et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395 10.1182/blood-2007-03-082404
9. J. Vardiman The classification of MDS: from FAB to WHO and beyond Leuk Res 36 2012 1453 1458 10.1016/j.leukres.2012.08.008
10. P.A. Wong, B. Fang, L. Zhang, X. Guo, S. Lee, and R. Schreck Loss of the Y chromosome an age-related or clonal phenomenon in acute myelogenous Arch Pathol Lab Med 2008 1329 1332
11. L. Malcovati, E. Hellström-Lindberg, D. Bowen, L. Adès, J. Cermak, C. Del Cañizo, and et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Blood 2013 1 66 10.1182/blood-2013-03-492884
12. W. Kern, C. Haferlach, S. Schnittger, T. Alpermann, and T. Haferlach Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics Haematologica 98 2013 201 207 10.3324/haematol.2012.066787
13. P. Valent, H.-P. Horny, J.M. Bennett, C. Fonatsch, U. Germing, P. Greenberg, and et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference Leuk Res 31 2007 727 736 10.1016/j.leukres.2006.11.009
14. K. Ogata, M.G. Della Porta, L. Malcovati, C. Picone, N. Yokose, A. Matsuda, and et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study Haematologica 94 2009 1066 1074 10.3324/haematol.2009.008532
15. D.A. Wells, M. Benesch, M.R. Loken, C. Vallejo, D. Myerson, W.M. Leisenring, and et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation Blood 102 2003 394 403 10.1182/blood-2002-09-2768
16. J.A. Cutler, D.A. Wells, A. van de Loosdrecht, M.E. de Baca, M.H. Kalnoski, B.K. Zehentner, and et al. Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias Cytom Part B Clin Cytom 80 2011 150 157 10.1002/cyto.b.20582
17. A. Van de Loosdrecht, and T. Westers Cutting edge: flow cytometry in myelodysplastic syndromes J Natl Compr Canc Netw 11 2013 892 902
18. T.M. Westers, R. Ireland, W. Kern, C. Alhan, J.S. Balleisen, P. Bettelheim, and et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group Leuk Off J Leuk Soc Am Leuk Res Fund UK 26 2012 1730 1741 10.1038/leu.2012.30
19. Q. Shen, J. Ouyang, G. Tang, E.J. Jabbour, G. Garcia-Manero, M. Routbort, and et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response Eur J Haematol 2014 10.1111/ejh.12477
20. N. Larsson, R. Billström, H. Lilljebjörn, C. Lassen, J. Richter, M. Ekblom, and et al. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells Cancer Gen Cytogenet 199 2010 89 95 10.1016/j.cancergencyto.2010.02.005
21. W. Kern, C. Haferlach, S. Schnittger, and T. Haferlach Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data Cancer 116 2010 4549 4563 10.1002/cncr.25353
22. F. Truong, B.R. Smith, D. Stachurski, J. Cerny, L.J. Medeiros, B.A. Woda, and et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study Leuk Res 33 2009 1039 1046 10.1016/j.leukres.2009.01.012
23. D. Stachurski, B.R. Smith, O. Pozdnyakova, M. Andersen, Z. Xiao, A. Raza, and et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls Leuk Res 32 2008 215 224 10.1016/j.leukres.2007.06.012
24. M.G. Della Porta, C. Picone, C. Pascutto, L. Malcovati, H. Tamura, H. Handa, and et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study Haematologica 97 2012 1209 1217 10.3324/haematol.2011.048421
25. S. Mathis, N. Chapuis, C. Debord, a Rouquette, I. Radford-Weiss, S. Park, and et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes Leukemia 27 2013 1981 1987 10.1038/leu.2013.178
26. P.L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-Manero, F. Solé, and et al. Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 2012 2454 2465 10.1182/blood-2012-03-420489
27. F. Wimazal, C. Fonatsch, R. Thalhammer, I. Schwarzinger, L. Müllauer, W.R. Sperr, and et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface Leuk Res 31 2007 1461 1468 10.1016/j.leukres.2007.03.015
28. P. Valent, and H.-P. Horny Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions Eur J Clin Investig 39 2009 548 553 10.1111/j.1365-2362.2009.02151.x
29. E. Papaemmanuil, M. Gerstung, L. Malcovati, S. Tauro, G. Gundem, P. Van Loo, and et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes Blood 122 2013 3616 3627 10.1182/blood-2013-08-518886 quiz 3699